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Hypertriglyceridemia is an independent risk factor for cardiovascular disease. Dietary interventions 
based on protein restriction (PR) reduce circulating triglycerides (TGs), but underlying mechanisms 
and clinical relevance remain unclear. Here, we show that 1 week of a protein-free diet without 
enforced calorie restriction significantly lowered circulating TGs in both lean and diet-induced 
obese mice. Mechanistically, the TG-lowering effect of PR was due, in part, to changes in very 
low–density lipoprotein (VLDL) metabolism both in liver and peripheral tissues. In the periphery, 
PR stimulated VLDL-TG consumption by increasing VLDL-bound APOA5 expression and promoting 
VLDL-TG hydrolysis and clearance from circulation. The PR-mediated increase in Apoa5 expression 
was controlled by the transcription factor CREBH, which coordinately regulated hepatic expression 
of fatty acid oxidation–related genes, including Fgf21 and Ppara. The CREBH-APOA5 axis activation 
upon PR was intact in mice lacking the GCN2-dependent amino acid–sensing arm of the integrated 
stress response. However, constitutive hepatic activation of the amino acid–responsive kinase 
mTORC1 compromised CREBH activation, leading to blunted APOA5 expression and PR-recalcitrant 
hypertriglyceridemia. PR also contributed to hypotriglyceridemia by reducing the rate of VLDL-TG 
secretion, independently of activation of the CREBH-APOA5 axis. Finally, a randomized controlled 
clinical trial revealed that 4–6 weeks of reduced protein intake (7%–9% of calories) decreased VLDL 
particle number, increased VLDL-bound APOA5 expression, and lowered plasma TGs, consistent 
with mechanistic conservation of PR-mediated hypotriglyceridemia in humans with translational 
potential as a nutraceutical intervention for dyslipidemia.
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Introduction
Hypertriglyceridemia is an independent risk factor for cardiovascular disease (1). When associated with 
other metabolic comorbidities, it often occurs concomitantly with high low-density lipoprotein (LDL) and 
low high-density lipoprotein (HDL) levels, constituting the denoted atherogenic lipid triad dyslipidemia 
(2–5). Despite this, existing therapeutic options are limited to modulation of  triglyceride (TG) synthesis 
or reduction of  very low–density lipoprotein (VLDL) secretion, thus highlighting the need for novel strat-
egies targeting alternate mechanisms with hypotriglyceridemic potential, such as increasing peripheral 
VLDL-TG clearance (6).
Dietary restriction (DR), defined as reduced food intake without malnutrition, is widely acknowledged 
for its pleiotropic benefits, including longevity extension, reduced cancer development, resistance to oxi-
dative stress, and improved metabolic fitness (7). In the latter context, DR has demonstrated efficacy in 
lowering circulating TGs and other cardio-metabolic risk factors in nonhuman primates (8) and humans 
(9). While impracticalities associated with long-term DR (defined here as greater than 1 week) limit direct 
clinical translation, we and others have demonstrated benefits from shorter periods of  DR lasting a week 
or less (defined here as short-term DR), which includes increased surgical stress resistance and improved 
metabolic fitness in mice (10–14). However, the precise mechanisms through which DR exerts its beneficial 
effects on lipid metabolism are not known.
From a nutritional standpoint, many of  the pleiotropic benefits of  short-term DR can be triggered by 
restriction of  dietary protein intake (protein restriction; PR) or essential amino acids (EAA), independent 
of  overall calorie intake. These benefits include resistance to hepatic ischemia reperfusion injury (IRI), 
increased energy expenditure, and significant reduction of  TGs, even during short-term PR interventions 
(13, 15–20). Amino acid–sensing pathways are implicated in controlling such systemic benefits in response 
to protein or EAA restriction. Amino acid insufficiency is detected via the general control nonderepress-
ible 2 (GCN2) kinase, which activates the integrated stress response (ISR), as demonstrated by increased 
phosphorylation of  the eukaryotic initiation factor 2α (eIF2α) and translation of  activating transcription 
factor 4 (ATF4). A different eIF2α kinase, the protein kinase R–like (PKR-like) ER kinase (PERK), is acti-
vated upon dietary methionine restriction (21), suggesting redundancy with GCN2 in triggering the ISR 
upon PR. Amino acid sufficiency, on the other hand, is sensed through the mechanistic target of  rapamycin 
complex 1 (mTORC1).
While GCN2 is required for benefits of  individual EAA restriction against IRI (22), it is dispensable in the 
context of  total PR, which instead requires downregulation of  mTORC1 (23). In the context of  lipid metabo-
lism, both amino acid–sensing pathways are implicated in regulating the interplay between lipid and amino 
acid metabolism. GCN2 activation by single EAA deprivation suppresses lipid metabolism by repressing the 
induction of  sterol regulatory element binding protein 1c–dependent SREBP1c-dependent (SREBP1c-depen-
dent) lipogenic gene expression (24). Conversely, mTORC1 activation in the context of  amino acid sufficiency 
promotes lipid synthesis via indirect regulation of  SREBP1c (25, 26). Nonetheless, the role of  these amino 
acid–responsive pathways in regulating the TG-lowering effects of  PR have not been investigated.
Nutritional status is also a key determinant of  VLDL-TG metabolism. TGs are transported primarily in 
chylomicrons in the fed state. In the fasted state, circulating TGs are transported predominantly in VLDL 
particles, which are assembled in the liver microsome compartment prior to secretion into circulation. Apo-
lipoproteins expressed in liver are embedded onto VLDL particles to serve important roles in peripheral TG 
clearance. For instance, while some apolipoproteins serve as particle receptor ligands (e.g., APOB), while 
others act as coregulators of  lipoprotein lipase (LPL) activity in periphery (e.g., APOC3, APOA5). Among 
these, APOA5 plays a pivotal role in facilitating TG hydrolysis from lipoprotein particles by stimulating 
LPL activity in the periphery (27, 28). Thus, mutations and polymorphisms affecting APOA5 function are 
common causes of  hypertriglyceridemia (29–31).
Apoa5 expression is regulated by multiple transcription factors that also respond to host nutritional 
status. These include repression by the liver X-receptor (LXR)/SREBP-1c (32) and induction by peroxi-
some proliferator-activated receptor α (PPARα) (33), thyroid hormone receptor (34), and cAMP-responsive 
element–binding protein hepatocyte-specific (CREBH) (35, 36). CREBH is an ER-tethered transcription 
factor regulated by intramembrane proteolysis (37) through poorly characterized mechanisms modulated 
by feeding/fasting cycles (38). While originally described as an ER stress effector protein, the finding that 
CREBH-KO mice are hypertriglyceridemic with concomitant changes in apolipoprotein expression has 
suggested a major role for this transcription factor in controlling TG homeostasis (35, 39, 40). CREBH also 
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regulates FGF21, a hormone that responds to nutritional cues, including protein deprivation (20) and sugar 
intake (41). FGF21 reduces TG levels (42) by increasing VLDL-TG disposal in white and brown adipose 
tissue (43). However, neither the effect of  PR in regulating CREBH activation, nor the involvement of  a 
potential CREBH-APOA5 axis in controlling TG levels during protein deprivation, have been investigated. 
Here, we sought to identify the mechanisms by which dietary protein intake exerts its hypotriglyceridemic 
effects and describe activation of  hepatic and peripheral events controlling VLDL-TG metabolism, regu-
lated through CREBH-APOA5–dependent and –independent mechanisms.
Results
Short-term dietary PR reduces circulating TGs independently of  total caloric intake via effects on VLDL-TG levels. To 
gain insight into the mechanism by which short-term DR reduces serum TG levels, we first explored the 
role of  total protein and calorie intake in the hypotriglyceridemic effect of  PR. To this end, B6D2F1 mice 
were fed with a complete (18% calories from protein) or protein-free (PF) diet (protein replaced by isocalo-
ric sucrose) provided either ad libitum (AL) or restricted by 50% of  total calories (calorie restriction; CR) 
for 1 week. The PF diet fed AL led to a more drastic reduction of  serum TGs than 50% CR (Figure 1A). 
This effect was not further accentuated upon enforced food restriction in the PF-CR group (Figure 1A). 
Reduction of  circulating TGs was confirmed using an unbiased serum lipidomic analysis, which revealed 
reduction in most individual TG species as a major change triggered by PR (Supplemental Figure 1; supple-
mental material available online with this article; https://doi.org/10.1172/jci.insight.99470DS1).
Serum TGs levels were significantly reduced in PR mice in the fed and fasted states (Figure 1B), sug-
gesting important changes in VLDL particles triggered during protein deprivation. This was confirmed 
in fractionation experiments using fast performance liquid chromatography (FPLC), which demonstrated 
a reduction of  VLDL-TG levels upon PR (Figure 1C). Also, APOB-100, which is present at 1 molecule 
per VLDL particle and is, thus, representative of  VLDL particle number, was reduced in serum upon PR 
(Figure 1D). Analysis of  TG content of  purified VLDL particles normalized to APOB-100 confirmed a 
significant reduction in the lipidation state of  PR-derived VLDL particles (Figure 1E). Thus, TG lowering 
during PR is associated with a reduction in VLDL particle number and lipidation state.
PR alters peripheral VLDL-TG consumption via changes in hepatic apolipoprotein expression. Along with 
VLDL particle lipidation and hepatic secretion, LPL-mediated TG hydrolysis in the periphery is a major 
determinant of  circulating TG levels. To investigate the potential contribution of  peripheral VLDL-TG 
consumption, we injected recombinant TG-rich lipoprotein particles containing radiolabeled TG (44) into 
mice fed a complete or PF diet for 1 week. We observed faster clearance of  radio-labeled TG from circula-
tion in PR mice (Figure 2A).
To test whether diet-induced changes in VLDL particles themselves contributed to increased VLDL-TG 
clearance, we purified endogenously radiolabeled TG-containing VLDL particles from mice on complete or 
PF diets (Supplemental Figure 2A), and we injected them into recipient mice fed a complete diet. Radiolabeled 
VLDL-TG derived from PR mice cleared significantly faster from circulation than radiolabeled VLDL-TG 
derived from mice fed a complete diet (Figure 2B and Supplemental Figure 2B), suggesting the existence of  
intrinsic differences in VLDL particle composition themselves, as a contributing factor to TG lowering by PR.
The apolipoprotein composition of  nascent lipoprotein particles plays an important role in regulating 
TG clearance in the periphery. We thus analyzed hepatic apolipoprotein gene expression as a function 
of  diet, finding significant decreases in Apoa2, Apoc3, and Apoe. Of  interest, we also observed a signifi-
cant increase in mRNA expression of  the hypolipidemic apolipoprotein gene Apoa5 upon PR (Figure 2C), 
which was also confirmed at the protein level (Figure 2D).
PR increased APOA5 localization in the ER of  hepatocytes (Figure 2E), where it is suitable for incor-
poration into nascent VLDL particles. Serum APOA5 levels were not significantly higher after 1 week of  
PR (Supplemental Figure 2C); however, due to the reduced number of  VLDL particles (Figure 1D), the 
APOA5/APOB ratio indicative of  APOA5 occupancy per VLDL particle was significantly increased (Fig-
ure 2F) and negatively correlated with serum TG levels (Figure 2G). To measure the relative contribution 
of  changes in APOA5 expression to PR-mediated TG lowering, we used whole-body APOA5-KO mice on 
an FVB genetic background and tested the hypotriglyceridemic response to PR. Interestingly, APOA5-KO 
serum TG levels were reduced by ~50% but remained significantly elevated relative to WT controls on a PF 
diet (Figure 2H). Taken together, these data point to a significant, although partial, contribution of  APOA5 
to the TG-lowering effects of  PR.
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CREBH regulates Apoa5 expression upon PR. We next sought to determine the mechanism by which PR 
controls Apoa5 expression. In humans, APOA5 is regulated by PPARα (45), as well as CREBH (36). Here, 
we confirmed the presence of  a highly conserved TCCACGTGGT-CREBH regulatory element in the pro-
motor region of  Apoa5 in mice and other mammals (Supplemental Figure 3, A and B). Immunoblotting 
with an antibody recognizing the amino-terminal fragment present in both the full-length, inactive (70 kDa) 
and the cleaved, active (45 kDa) forms of  CREBH revealed an increase in the cleaved form in total liver 
lysates of  mice on PR (Figure 3A). Cell fractionation experiments and confocal microscopy analysis con-
firmed nuclear enrichment of  the cleaved form (Figure 3, B and C) compared with cytoplasmic fractions 
(Supplemental Figure 3C). Also, analysis of  hepatic expression of  direct CREBH targets including Pepck, 
Apoa4, Cyp4a10, and Fgf21 (35, 46–48) revealed an increase in livers of  mice on PR (Figure 3D). Overex-
pression of  HA-tagged active human CREBH (46) in human HepG-2 hepatoma cells resulted in nuclear 
localization (Figure 3E) and increased Apoa5 mRNA expression (Figure 3F). Finally, ChIP–quantitative 
PCR (ChIP-qPCR) analysis revealed enrichment of  CREBH on the Apoa5 promoter in mouse livers inde-
pendent of  diet (Figure 3G). Together, these results are consistent with CREBH activation and regulation 
of  APOA5 expression upon PR. We used whole-body CREBH-KO to explore the requirement of  this tran-
scription factor during PR. As predicted, hepatic Apoa5 mRNA was reduced in CREBH-KO mice relative 
to controls (Figure 3H). PR-induced Fgf21 expression was also significantly reduced (Figure 3I). Expression 
of  PPARα targets Acadvl and Ctp1a, as well as Ppara mRNA itself, were reduced in CREBH-KO livers at 
baseline and/or upon PR (Figure 3J). These results are consistent with coordinated regulation of  fatty acid 
oxidation (FAO) gene expression programs controlled by CREBH and PPARα.
Figure 1. Short-term dietary protein restric-
tion reduces circulating TGs independently 
of total caloric intake via effects on VLDL-TG 
levels. B6D2F1 mice were fed the indicated 
complete (C, 18% protein content) or protein-
free (PF, protein replaced with isocaloric 
sucrose) diet for 1 week prior to analysis. (A) 
Serum triglyceride (TG) concentrations in 
mice fed the indicated diet on an ad libitum 
basis (AL) or restricted daily (CR) by 50% (n = 
5/group; 2-way ANOVA with Sidak post-hoc 
test between the indicated groups. (B) Serum 
TG in mice on the indicated diet (n = 4–5/
group; 2-tailed Student’s t test between diets 
within fed or fasted state). (C) TG levels in 
FPLC fractions from pooled plasma samples 
(n = 5/group; VLDL, very low–density lipopro-
tein; IDL, intermediate-density lipoprotein; 
LDL, low-density lipoprotein; HDL, high-
density lipoprotein). (D) Serum APOB-100 
concentration representative of circulating 
VLDL particle number (n = 5/group; 2-tailed 
Student’s t test). (E) TG content of purified 
VLDL particles expressed per unit APOB-
100, indicative of VLDL particle lipidation (n 
= 3/group; 2-tailed Student’s t test). Data 
expressed as mean ± SD; *P < 0.05; **P < 
0.01; ***P < 0.001; ****P < 0.0001.
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The blunted capacity to upregulate APOA5 in CREBH-KO mice was also evident at the protein 
level (Figure 3K) and in serum (Supplemental Figure 3D), correlating with a significant reduction 
of  APOA5 expression on the surface of  VLDL particles (Figure 3L) without any significant change 
in VLDL particle number between genotypes (Supplemental Figure 3E). Interestingly, circulating 
FGF21 levels upon PR were also significantly decreased in PR-CREBH–KO vs. WT mice (Figure 3M). 
Reduced APOA5 and FGF21 levels correlated with a ~50% reduction of  plasma TG in CREBH-KO 
mice (Figure 3N). Nonetheless, circulating TG levels remained significantly elevated relative to WT 
controls on a PF diet (Figure 3N). Together, these results are consistent with a partial role for CREBH 
Figure 2. Protein restriction alters VLDL-TG consumption via changes in hepatic apolipoprotein expression. (A and B) Time-dependent clearance of 
radiolabeled TG from the following circulating lipoprotein particles: (A) [3H]-triolein-labeled recombinant lipoprotein particles injected into mice fed a 
complete (C) or protein-free (PF) diet (n = 7/group); or (B) [3H]-palmitate-labeled and purified VLDL particles from mice on C or PF diets, and injected into 
complete-fed mice (n = 4/group; multiple t tests between diet groups with Holm-Sidak post-hoc test). (C) Hepatic mRNA expression of apolipoprotein-
encoding genes from mice on the indicated diet (n = 4–11/group; 2-tailed Student’s t test). (D) Immunoblot of hepatic APOA5 protein expression. Below, 
quantitation normalized to tubulin and expressed in arbitrary units (AU, n = 5/group; 2-tailed Student’s t test). (E) Representative confocal microscopic 
images taken with a 63× objective from livers of mice on the indicated diet showing the ER marker KDEL (green), APOA5 (red), nuclei (DNA stained with 
DAPI, blue) superimposed to differential interference contrast (DIC) image and a composite image. Scale bar: 20 μm. (F) Circulating VLDL-bound APOA5 
levels in mice on the indicated diet, expressed as the ratio of serum APOA5 to APOB-100 as measured by ELISA (n = 5/group; Mann-Whitney U test). (G) 
Correlation analysis between serum TG and APOA5. Each dot represents an individual mouse; r, Pearson’s coefficient. (H) Fasted serum TG levels in whole 
body APOA5-KO or control FVB WT mice on the indicated diet (n = 4/group; 2-way ANOVA with Sidak post-hoc test between the indicated groups). Data 
expressed as mean ± SD; **P < 0.01, ***P < 0.001; ****P < 0.0001.
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Figure 3. CREBH regulates Apoa5 expression upon protein restriction. (A–D) B6D2F1 mice were fed complete (C) or protein free (PF) diet for 1 week prior to 
analysis. (A) Immunoblot of CREBH full-length (FL) and cleaved fragment (CF) in liver extracts; 2 left lanes, CREBH-KO antibody specificity controls. Right, 
quantitation of CREBH CF normalized to FL and expressed in arbitrary units (AU; n = 5/group; 2-tailed Student’s t test). (B) CREBH CF immunoblot in liver 
nuclear extracts. Right, quantitation normalized to lamin A/C (n = 5/group; 2-tailed Student’s t test). (C) Representative confocal microscopic images (20× 
objective) of livers stained for CREBH amino-terminus (fire-red look-up intensity table visualization), DAPI-stained nuclei (DNA, blue) super-imposed onto 
the corresponding differential interference contract (DIC) image, and composite. Scale bars: 50 µm. Right micrograph, 10× digital magnification of indi-
cated area. (D) Hepatic mRNA expression of CREBH targets Apoa4, Cyp4a10, Pepck, and Fgf21 (n = 5–10/group; 2-tailed Student’s t test). (E) Representa-
tive confocal microscopic images (63× objective) of HepG-2 cells transfected with hemagglutinin-tagged (HA-tagged) human CREBH CF (hCREBH [CF]-HA) 
vs. empty vector (Mock) and labeled with anti-HA antibody or DAPI (DNA) as indicated. Scale bars: 10 µm. (F) mRNA expression of human Apoa5 from cells 
transfected as in E; data in triplicate from one representative experiment of 3; 2-tailed Student’s t test. (G) ChIP of CREBH from livers of mice on the indi-
cated diet, followed by qPCR analysis of the region flanking the predicted CREBH binding motif in the Apoa5 promoter (n = 3/group; 2-way ANOVA with 
Sidak post-hoc test between indicated groups). (H–N) CREBH-KO or WT control littermates were fed the indicated diet for 1 week prior to analysis. (H–J) 
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in PR-mediated hypotriglyceridemia via coordinated transcriptional control of  factors involved in sys-
temic FAO, including hepatic PPARα, circulating FGF21, and VLDL-bound APOA5.
Role of  GCN2, PERK, and the ISR in CREBH activation upon PR. We next explored the role of  ami-
no acid–sensing pathways in regulating activation of  the CREBH-APOA5 hepatic axis. Consistent with 
GCN2 activation, we observed increased eIF2α phosphorylation and ATF4 protein expression following 
a week on PR (Figure 4A and Supplemental Figure 4A). However, CREBH cleavage, APOA5 and FGF21 
induction, and serum TG lowering upon PR were all intact in global GCN2-KO mice (Figure 4, B–E).
CREBH activation was originally described in the context of  the ER stress–inducing agent thap-
sagargin (37), which activates the ISR through the eIF2α kinase, PERK (21). Interestingly, PERK was 
activated upon PR (Figure 4F), even in the absence of  GCN2 (Figure 4G), as reflected by increased 
eIF2α phosphorylation and expression of  ATF4 target genes including asparagine synthetase (Asns) and 
Atf4 itself  (Figure 4, H and I). Additionally, PR failed to activate ER stress markers IRE-1α, TRAF2, or 
JNK-1 (Supplemental Figure 4B), suggesting that CREBH activation upon PR does not require ER stress 
per se, but rather could result from ISR activation downstream of  GCN2 and/or PERK, or via PERK 
activation independently of  the ISR.
Constitutive mTORC1 signaling inhibits CREBH activation. Signal transduction via mTORC1, determined 
based on S6 phosphorylation, was reduced following a week of  PR (Figure 5A). To test the potential role 
of  this signal transduction pathway in CREBH activation, we employed mice bearing hepatocyte-specific 
deletion of  the mTORC1 negative regulator TSC1 (liver-specific TSC1–KO; LiTSC1-KO), which display 
constitutive and PR-recalcitrant hepatic mTORC1 activation (23). Importantly, LiTSC1-KO mice subjected 
to PR failed to induce CREBH cleavage (Figure 5B), Apoa5 gene expression (Figure 5C), or hepatic APOA5 
protein expression (Figure 5D) upon PR. Inhibition of  mTORC1 activity with rapamycin rescued Apoa5 
mRNA expression in LiTSC1-KO mice (Figure 5E). However, hepatocyte-specific deletion of  the activating 
mTORC1 subunit Raptor (LiRaptor-KO) was insufficient to activate CREBH on a complete diet, although it 
did not prevent CREBH activation upon PR (Figure 5F). Together, these data are consistent with mTORC1 
as a negative regulator of  CREBH activation by another trigger, such as PR.
Reduced APOA5 in LiTSC1-KO mice correlated with hypertriglyceridemia at baseline that was 
refractory to the TG lowering effect of  PR (Figure 5G). Also, LiTSC1-KO mice had lower VLDL-
surface bound APOA5 expression (Figure 5H and Supplemental Figure 5, A and B), which negatively 
correlated with serum TG levels (Figure 5I). TG content of  purified VLDL particles derived from 
LiTSC1-KO serum remained high after a week in PR (Figure 5J), consistent with decreased peripheral 
VLDL-TG hydrolysis as a result of  decreased APOA5 lipoprotein surface expression. Surprisingly, 
despite the loss of  CREBH induction and PR-recalcitrant hypertriglyceridemia, the induction of  circu-
lating FGF21 upon PR was normal (Figure 5K).
Finally, we considered the potential of  mTORC1 activation to contribute to hypertriglyceridemia via 
effects on SREBP1c-dependent lipogenesis. However, reduction in hepatic SREBP1c protein and target 
lipogenic gene expression observed in WT mice upon PR (Supplemental Figure 5, C and D) was intact in 
LiTSC1-KO mice, with Fasn mRNA expression significantly reduced at baseline and further reduced upon 
PR (Supplemental Figure 5E). Taken together, these data suggest that increased mTORC1 signaling can 
prevent the hypotriglyceridemic effects of  PR, in part, through effects on CREBH activation and APOA5 
expression — but independently of  hepatic lipogenesis and despite elevated circulating FGF21.
Reduced hepatic VLDL particle secretion rate contributes to TG lowering upon PR independently of  CREBH-
APOA5 activation. The partial yet significant TG-lowering effects of  PR observed in hypertriglyceride-
mic APOA5-KO and CREBH-KO models (Figure 2H and Figure 3N) suggested a mechanism of  TG 
lowering independent of  the increase in fat oxidation/consumption coordinately controlled by CREBH 
and PPARα and their downstream effectors including APOA5 and FGF21. To identify such a CREBH-
APOA5–independent mechanism, we explored additional points controlling TG homeostasis.
Hepatic mRNA levels of Apoa5 (H), Fgf21 (I), and the Pparα targets Acadvl, Ctp1a, and Pparα itself (J) (n = 4/group; 2-way ANOVA with Sidak post-hoc test 
between indicated groups). (K) Immunoblot of hepatic APOA5; below, quantitation normalized to tubulin (n = 3/group; 2-way ANOVA with Sidak post-hoc 
test between indicated groups). (L–M) VLDL-bound APOA5 levels expressed as the ratio of serum APOA5 to APOB-100 (L) and serum FGF21 levels (M) (n = 
4/group; 2-way ANOVA with Sidak post-hoc test between indicated groups). (N) Fasted serum TG concentrations pooled from 3 independent experiments 
including male and female WT and CREBH-KO mice (2-way ANOVA with Sidak post-hoc test between indicated groups). Data expressed as mean ± SD;  
*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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Consistent with reduced steady-state circulating VLDL particle number upon PR in WT mice (Fig-
ure 1D), VLDL secretion rate — measured after tyloxapol administration — was also reduced upon PR 
(Figure 6A). Importantly, the magnitude of  the PR-mediated reduction in VLDL secretion rate upon 
tyloxapol challenge was similar between CREBH-KO and control mice (Figure 6B). In contrast, VLDL 
secretion rate was not significantly different upon PR in LiTSC1-KO mice (Figure 6C), reminiscent of  
their recalcitrance to TG lowering upon PR (Figure 5G).
To better understand the CREBH-independent effects of  PR on VLDL secretion rate, we looked at de 
novo VLDL particle biogenesis in WT mice. Hepatic free fatty acid (FFA) uptake (Supplemental Figure 6A), 
hepatic mRNA expression of  genes involved in FFA esterification (Supplemental Figure 6B), total hepatic TG 
levels after tyloxapol (Supplemental Figure 6C), and hepatic levels of  APOB and MTTP proteins involved in 
VLDL particle production (Supplemental Figure 6D) were all similar between diet groups, with the exception 
of  Gpat1 mRNA, which was significantly reduced upon PR. Interestingly, incorporation of  radiolabeled pal-
mitate from a portal vein infusion of  a lipid bolus into de novo–synthesized VLDL particles was significantly 
Figure 4. Role of GCN2, PERK, and the integrated stress response in CREBH activation upon protein restriction. (A–I) WT or GCN2-KO mice were fed the indi-
cated control (C) or protein-free (PF) diet for 1 week prior to analysis in the 4-hour fasted state. (A) Immunoblot of phospho- and total eIF2α in liver extracts of 
WT mice. Right, quantitation of phospho- eIF2α normalized to total expressed in arbitrary units (AU) (n = 5/group; 2-tailed Student’s t test). (B) Immunoblot 
of hepatic CREBH. Right, quantitation of CREBH cleaved form (CF) normalized to full-length (FL) (n = 3–7; 2-way ANOVA with Sidak post-hoc test between the 
indicated groups). (C) Immunoblot of hepatic APOA5 expression. Right, quantitation normalized to tubulin (n = 4–14/group; 2-way ANOVA with Sidak post-hoc 
test between the indicated groups). Due to the number of samples, blots in B and C were run on separate gels with the same complete WT control on each for 
between-blot normalization. (D) Serum FGF21 levels (n = 5/group, 2-way ANOVA with Sidak post-hoc test between the indicated groups). (E) Serum TG (n = 5/
group; 2-way ANOVA with Sidak post-hoc test between the indicated groups). (F) Immunoblot of phospho- and total PERK in liver extracts. Right, quantita-
tion of phospho-PERK normalized to total (n = 3/group; 2-tailed Student’s t test). (G) Immunoblot of phospho- and total eIF2α in liver extracts (n = 4–5/group; 
1-way ANOVA with Tukey post-hoc test between the indicated groups). (H and I) Hepatic mRNA expression of Asns (H) and Atf4 (I) (n = 4–5/group; 2-way 
ANOVA with Sidak post-hoc test between the indicated groups). Data expressed as mean ± SD; *P < 0.05; **P < 0.01; ***P < 0.00; ****P < 0.0001.
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Figure 5. Constitutive mTORC1 signaling inhibits CREBH activation. (A) Immunoblot of phospho- and total S6 in liver extracts. Below, quantita-
tion of phospho-S6 normalized to total and expressed in arbitrary units (AU); n = 4–5/group; 2-tailed Student’s t test. (B–E and G–K) Liver-specific 
TSC1–KO (LiTSC1-KO; TSC1fl/fl|Albumin-Cre+/–) mice and littermate controls (TSC1fl/fl|Albumin-Cre–/–) fed a complete (C) or protein-free (PF) diet for 1 
week prior to analysis. (B) Immunoblot of CREBH full-length (FL) and cleaved fragment (CF) in liver extracts. Below, quantitation of CF normalized to 
FL (n = 3/group; 2-way ANOVA with Sidak post-hoc test between the indicated groups). (C) Hepatic Apoa5 mRNA expression (n = 7–8/group; 2-way 
ANOVA with Sidak post-hoc test between indicated groups). (D) Immunoblot of hepatic APOA5. Below, quantitation normalized to tubulin (n = 3/
group; 2-way ANOVA with Sidak post-hoc test between indicated groups; interaction P = 0.01/30% variation; genotype P = 0.02/22% variation; diet 
P = 0.02/24% variation). (E) Apoa5 mRNA expression from livers of LiTSC1-KO mice injected once daily with rapamycin (1 mg/kg) or vehicle (Veh) for 
indicated days of treatment (Tx); n = 3–4/group; 1-way ANOVA with Dunnett post-hoc test compared with vehicle control. (F) Immunoblot of hepatic 
CREBH in mice with hepatocyte-specific Raptor deletion (LiRaptor-KO; Raptorfl/fl|Albumin-Cre+/–) vs. littermate controls (Raptorfl/fl|Albumin-Cre–/–). 
Below, quantitation of CREBH CF normalized to FL (n = 3/group; 2-way ANOVA with Sidak post-hoc test between indicated groups). (G) Serum TG 
(n = 13–14/group; 2-way ANOVA with Sidak post-hoc test between indicated groups). (H) VLDL-bound APOA5 levels expressed as the ratio of serum 
APOA5 to APOB-100 (n = 5–7/group; 2-way ANOVA with Sidak post-hoc test between indicated groups). (I) Correlation analysis between serum TG 
and circulating APOA5. Each symbol represents an individual mouse; r, Pearson’s coefficient. (J) TG content of VLDL particles purified from serum 
of WT and LiTSC1-KO mice expressed per unit APOB-100 indicative of VLDL particle lipidation (n = 3/group; 2-way ANOVA with Sidak post-hoc test 
between indicated groups). (K) Serum FGF21 levels (n = 4/group; 2-way ANOVA with Sidak post-hoc test between indicated groups). Data expressed 
as mean ± SD; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
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elevated upon PR (Supplemental Figure 6E), while the lipidation of  VLDL particles in tyloxapol-treated ani-
mals was not significantly different between diet groups (Supplemental Figure 6F). These data are consistent 
with an intact ability to lipidate VLDL particles and suggests TG and FFA availability for particle incorpora-
tion as a limiting factor in VLDL biogenesis and secretion upon PR.
PR improves TG homeostasis in dyslipidemic models. We next explored the hypotriglyceridemic effects 
of  PR in different clinically relevant models of  metabolic disease. We started with a diet-induced 
model of  obesity and insulin resistance consisting of  B6D2F1 mice fed for 3 months on a high-fat diet 
(HFD; 60% calories from fat, 20% from protein, 20% from carbohydrates). One week on a PF-HFD 
(60% calories from fat, 40% from carbohydrates; Supplemental Table 1) resulted in similar global 
metabolic effects, as observed in lean mice, including increased CREBH cleavage (Figure 7A), upregu-
lation of  hepatic APOA5 protein expression (Figure 7B), and reduced serum TGs under fed and fasted 
conditions (Figure 7C) relative to control mice maintained on the HFD.
Because HFD feeding resulted in only modest TG elevation in B6D2F1 mice, we combined HFD 
with a genetic model lacking LDLR receptor (LDLR-KO). After 3 months on a HFD, 1 week of  PF-
HFD feeding led to a significant induction of  CREBH cleavage (Figure 7D), increased hepatic and 
VLDL-bound APOA5 expression (Figures 7, E and F), and reduced serum TGs (Figure 7G). Consistent 
with CREBH and PPARα activation, FGF21 levels were also significantly elevated in both dyslipidemic 
models (Figure 7H). Together, these results demonstrate that PR can activate CREBH under conditions 
Figure 6. Reduced hepatic VLDL particle secretion 
rate contributes to TG lowering upon protein restric-
tion independently of CREBH-APOA5 activation. 
(A–C) Hepatic VLDL secretion rate measured following 
tyloxapol injection in mice fed a complete (C) or protein-
free (PF) diet. (A) B6D2F1 WT mice (n = 14/group); (B) 
CREBH-KO and WT littermate control mice (n = 4/group); 
and (C) LiTSC1-KO (TSC1fl/fl|Albumin-Cre+/–) and control 
(Cont, TSC1fl/fl|Albumin-Cre–/–) littermate mice (n = 5–9/
group). 2-tailed Student’s t tests using peak AUC from 
baselined TG values between diets within genotypes. 
Data expressed as mean ± SD; *P < 0.05; **P < 0.01; 
***P < 0.001.
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of  metabolic stress triggered by chronic HFD feeding, even in the absence of  lipoprotein receptor–medi-
ated lipoprotein uptake.
Moderate PR increases APOA5 expression and reduces TG levels in mice and humans. Finally, we sought to 
test whether the increase in APOA5 expression and decrease in circulating TG levels observed in lean and 
obese rodents on a PF diet can be translated to humans at achievable levels of  PR. To this end, we first 
titrated protein content in the rodent diet from 18%–0%, replacing the remaining calories with isocaloric 
sucrose. This resulted in a dose-dependent increase in CREBH cleavage (Figure 8A), APOA5 expression 
(Figure 8B), PERK phosphorylation (Figure 8C), ATF4 expression (Figure 8D), and serum FGF21 (Figure 
8E) and a decrease in serum TGs (Figure 8F) within 1 week.
Having established that benefits of  a PF diet could be recapitulated at moderate levels of  PR, we 
next measured plasma APOB-100, APOA5, and TGs in humans before and after 4–6 weeks of  feed-
ing on a customized isocaloric 8%–9% protein diet vs. control subjects who continued to eat normally. 
These samples were obtained as part of  a clinical trial designed to test the effects of  PR in patients 
with prostate cancer for approximately 1 month prior to prostatectomy relative to those maintained 
on their normal diet (49). As in rodents, PR significantly reduced plasma APOB-100 levels, indicative 
of  a decrease in circulating VLDL particle number (Figure 8G). PR also significantly increased plas-
ma APOA5 (Figure 8H) and the APOA5/APOB-100 ratio (Figure 8I), concomitant with a significant 
decrease in plasma TG levels (Figure 8J). Together, these data suggest that mechanisms of  TG lowering 
by PR are conserved between mice and humans.
Discussion
A model for CREBH-dependent and -independent mechanisms of  PR-mediated hypotriglyceridemia 
is presented in Figure 9. CREBH activation upon PR is part of  a coordinated transcriptional response 
involving PPARα and mediating an overall increase in FAO on the organismal level through regulation 
Figure 7. PR improves TG homeostasis in dyslipidemic models. (A–H) B6D2F1 mice (A–C and H) or low-density lipoprotein receptor KO (LDLR-KO, D–H) 
mice were fed a high-fat diet (HFD) for 3 months prior to switching half to an isocaloric protein-free HFD (PF-HFD) for 1 week. Metabolic and molecular 
analyses were performed after a 4-hour fast. (A and D) Immunoblot of CREBH full-length (FL) and cleaved form (CF) in liver extracts with quantitation 
below of CF normalized to full-length (arbitrary units [AU]; n = 4–5/group; 2-tailed Student’s t test). (B and E) Immunoblot of APOA5 in liver extracts with 
quantitation below normalized to tubulin; n = 3–4/group; 2-tailed Student’s t test. (C and G) Serum TG in fed or 4-hour–fasted states as indicated (n = 
4–5/group; 2-tailed Student’s t test between diet groups within fed or fasted state). (F) Circulating VLDL-bound APOA5 levels expressed as the ratio of 
serum APOA5 to APOB-100 (n = 4/group; 2-tailed Student’s t test). (H) Serum FGF21 levels (n = 4/group; 2-tailed Student’s t test within genotype between 
diets). Data expressed as mean ± SD; *P < 0.05, **P < 0.01, ***P < 0.001.
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of  key players, including APOA5 and FGF21. PR also reduced the rate of  VLDL secretion, resulting in 
VLDL-TG lowering independently of  CREBH or activation of  the FAO program it participates in.
APOA5 and FGF21 as effectors of  PR-mediated TG lowering. Here, we found that PR altered hepatic apoli-
poprotein expression, increasing the levels of  APOA5 in liver and VLDL particles, where it stimulated TG 
clearance via stimulation of  peripheral LPL activity (28, 50). Hepatic APOA5 can also reduce TG avail-
ability for lipoprotein lipidation by promoting intrahepatic TG lipolysis, thus decreasing the number and 
rate of  VLDL particle export (28, 50, 51). However, future experiments are required to dissect the potential 
contribution of  intrahepatic vs. VLDL-bound APOA5 in PR-mediated TG lowering.
Like APOA5, FGF21 is elevated upon PR (20, 52) — as well as in response to sugar (53) — and has 
an established role in promoting TG clearance via activation of  white and brown adipose tissue (43) and 
increasing energy expenditure via central and peripheral mechanisms — for example, through increased 
expression of  uncoupling proteins leading to energy dissipation as heat (54, 55). Also, like Apoa5, hepatic 
Fgf21 is controlled on the transcriptional level by CREBH and PPARα (48). Because FGF21 was not fully 
upregulated upon PR in CREBH-KO mice, the partial TG lowering in this model could be ascribed to the 
absence of  a normal FGF21 response. However, the observation that FGF21 was normally elevated upon 
PR in the LiTSC1-KO model but failed to reduce hypertriglyceridemia argues that FGF21 expression alone 
is insufficient to lower circulating TGs. Considering the dysregulation of  APOA5 at baseline and upon PR 
in the LiTSC1-KO model, and the severe hypertriglyceridemia of  the APOA5-KO model, an interdepen-
dence between APOA5, FGF21, and perhaps other PPARα targets in TG lowering by PR seems likely. 
Future studies are required to sort out the relative contribution of  each to TG lowering and how these fac-
tors interact with one another, as well as the contribution of  other macronutrients such as sucrose.
Figure 8. Moderate protein restriction increases APOA5 expression and reduces TG levels in mice and humans. (A–F) Titration of protein restriction 
(18%–0% protein replaced with isocaloric sucrose) in B6D2F1 mice for 1 week. Immunoblot analyses of (A) CREBH full-length (FL) and cleaved form (CF), 
(B) APOA5, (C) PERK phosphorylation, and (D) ATF4 protein expression in whole liver extracts. For quantitation at right of each blot, samples were binned 
in 3 groups based on the level of dietary protein (high, 18%–10%; medium, 8%–6%; low, 4%–0%; n = 4–6/group; 1-way ANOVA with Dunnett post-hoc 
test compared with the high protein group). (E and F) Serum FGF21 (E) and TG (F) levels; 1-way ANOVA with Dunnett post-hoc test compared with the 18% 
protein group. (G–J) Effect of a low-protein diet in humans. Patients were randomized to control or protein restricted (PR, 7%–9% of energy from protein) 
diets; blood samples were taken before or after 4–6 weeks on the indicated diet (n = 19 per group; paired t test comparing parameter before and after diet). 
(G) Plasma APOB-100 concentration representative of circulating VLDL particle number. (H) Plasma APOA5. (I) VLDL-bound APOA5 levels expressed as the 
ratio of plasma APOA5 to APOB-100. (J) Plasma TG levels. Data expressed as mean ± SD; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.001.
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Reciprocal regulation of  pro-oxidative programs by PPARα and CREBH upon PR. Like CREBH, PPARα 
regulates fat oxidation via transcriptional control of  FAO machinery, FGF21, and even APOA5 in humans 
(mouse Apoa5 lacks a PPARα binding site; ref. 56). Activation of  PPARα with fibrates is a pharmaco-
logical approach to treating hypertriglyceridemia, often in combination with statins. PPARα also regulates 
CREBH on the transcriptional level (38, 57) and is activated by PR (57), although — like CREBH — the 
mechanism of  activation remains unclear.
Here, we found that PR is a powerful inducer of  CREBH cleavage and activation, and that one of  the 
genes that it regulates directly or indirectly encodes PPARα. Thus, these 2 transcription factors involved in 
promoting FAO appear to reciprocally regulate each other. This finding also suggests a potentially novel 
mechanism by which PR can activate PPARα. However, because CREBH is not absolutely required for 
basal or PR-mediated expression of  these genes, some of  the TG lowering observed upon PR could be 
due to residual APOA5, FGF21, and PPARα expression. Future experiments are, thus, required to better 
understand the relative contribution of  these transcription factors to the coordinated expression of  genes 
controlling FAO upon PR on the organismal level.
Mechanisms of  CREBH regulation by dietary PR. While links between dietary amino acid intake and 
hepatic lipid metabolism have been inferred based on the ability of  methionine/choline-deficient diets to 
increase hepatic steatosis (58), Guo and Cavener first demonstrated a molecular link between amino acid 
sensing and lipid metabolism (24). They observed that GCN2-KO mice fed a leucine-deficient diet devel-
op liver steatosis due to the failure to suppress SREBP1c-dependent lipogenesis. However, the circulating 
TG-lowering effects of  leucine deficiency (24) or methionine restriction (21), as well as other metabolic 
responses to PR (17), remain mostly intact, if  slightly delayed, in global GCN2-KO mice, similar to our 
findings here. Interestingly, the ER-bound eIF2α kinase PERK was also activated in liver upon PR, as 
reported previously upon methionine restriction (21). While this can explain the activation of  the ISR in 
the absence of  GCN2, it does not necessarily imply that the ISR is required for TG lowering. Future studies 
are required to better understand the mechanism of  PR-mediated PERK activation and its requirement, if  
any, in TG lowering upon PR.
Although mTORC1 positively regulates the prolipogenic transcription factor SREBP-1c, LTSC1-KO mice 
with constitutive hepatic mTORC1 activity do not have fatty livers, likely as a result of  compromised insulin 
signaling in this model (23, 26). Nonetheless, we report here that these mice are hypertriglyceridemic on a 
complete diet and that this is maintained on PR, correlating with the failure to activate CREBH or APOA5.
The molecular details of  CREBH cleavage and activation remain unknown. CREBH was originally 
identified as an ER stress–responsive transcription factor (37, 46, 59) and was subsequently linked to carbo-
hydrate and TG metabolism (35, 39), as well as fasting (47). PR did not appear to activate ER stress, but it 
did trigger the ISR through at least 2 different kinases, GCN2 and PERK. While the GCN2 kinase was not 
Figure 9. Model of dietary protein control of TG 
homeostasis via effects on hepatic VLDL-TG metabo-
lism. Green lines denote pathways activated during 
protein restriction; red lines depict downregulated 
pathways. Dashed lines represent events for which no 
precise mechanism of regulation is known. Bold char-
acters represent mediators activated during PR. Black 
arrows connect described effectors with the ultimate 
TG-lowering benefit of PR. FAO, fatty acid oxidation; 
ISR, integrated stress response.
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required for CREBH activation upon PR, future experiments are required to test the requirement for PERK 
and whether the ISR or some other ER-related function of  PERK is involved.
Decreased hepatic VLDL secretion rate as a CREBH-independent mechanism of  TG lowering by PR. PR also result-
ed in a reduced VLDL secretion rate independently of CREBH that contributed to the partial hypotriglyc-
eridemic effect observed during short-term PR in CREBH-KO and APOA5-KO models. Interestingly, in the 
LiTSC1-KO model, which was both hypertriglyceridemic and recalcitrant to PR-mediated TG lowering, basal 
VLDL secretion rate on a complete diet was lower than in WT and unchanged by PR, while VLDL particle lip-
idation remained high independently of diet. These data suggest that the change in VLDL secretion rate upon 
PR, rather than the basal rate per se, may be the critical factor in CREBH-independent TG lowering by PR.
Future experiments are also required to better understand the mechanism underlying the change in secre-
tion rate induced by PR, as neither changes in hepatic TG nor APOB levels could readily account for this. PR 
mice also produced normally lipidated VLDL particles (albeit at a slower rate) when LPL was inhibited and 
had an increased capacity to incorporate radiolabeled palmitate into VLDL particles in the context of a bolus 
injection of lipid into the portal vein. Based on the increase in hepatic FAO controlled by the PPARα program, 
one possibility is that hepatic TGs are somehow sequestered from VLDL biosynthesis for lipid oxidation.
Translational potential. Although reduced calorie, fat, and sugar intake and other behavioral modifications 
such as exercise are the first line of treatment of elevated triglyceride levels (6), the preclinical and clinical data 
presented here suggest that reduced protein intake can lower TGs, even without CR. This has important impli-
cations for translation due to the inherent difficulties associated with enforced food restriction. Most important-
ly, PR at sustainable levels of 7%–9% of total calorie intake was sufficient to reduce VLDL particle number and 
increase APOA5 expression concomitant with a reduction in TG levels in humans. However, future studies are 
required to determine the timing of onset of benefits, as previous studies have observed either no change (13) 
or increase in TG (60) within 3–7 days of low-protein (8%–10% calories) intake in people, with the additional 
caveat that both studies also reported a significant increase in total energy intake during this period.
Methods
Humans
Plasma samples from patients before and 4–6 weeks after PR were obtained from consented research volun-
teers registered under clinicaltrials.gov identifier NCT01692587 to test the effects of  PR on prostate cancer 
growth as reported previously (49). After baseline screening, participants were allocated with a 1:1 ratio into 
a control (n = 19) or the PR diet group (n = 19). The control subjects continued their usual diet, while the 
volunteers randomized to the PR diet were fed customized isocaloric PR experimental meals prepared by the 
Metabolic Kitchen of  Washington University CARS (St. Louis, Missouri, USA). In the PR menus, dietary 
protein intake was decreased to the dietary reference intake (DRI) for total protein. For adult males, the DRI 
is 56 g per day. To provide the participants with isocaloric menus, 3 calorie levels were available: 2,300 calo-
ries; 2,600 calories; and 2,900 calories. The menus were planned to provide a similar percent of  calories from 
protein (7%–9%) for the 3 calorie levels. The intakes of  protein were 56–60 g per day. Individualized energy 
intakes were estimated from a 4-day food diary and 2 formulas for estimating energy expenditure: Harris 
Benedict equation and Cunningham equation (include body composition and physical activity factors). The 
PR participants received a calorie level that was estimated to maintain body weight. Compliance with the iso-
caloric lower protein diet for volunteers randomized to PR was assessed by means of  the daily meal checklist.
Mice
Young adult male B6D2F1/J (stock no. 100006) and LDLR-KO (stock no. 005061) mice were purchased 
from the Jackson Laboratory. APOA5-KO mice on a FVB/NJ background were provided in house. 
Congenic FVB/NJ controls for the experiments were purchased from the Jackson Laboratory (stock no. 
001800). CREBH-KO mice (Creb3l3tm1.1Sad on a mixed 129/CD1/FVB/B6 background) were cryorecov-
ered from a previously described strain (61) at the Jackson Laboratory and bred in our facility. LiTSC1-
KO (TSC1fl/fl|Albumin-Cre+/–) and littermate control (TSC1fl/fl|Albumin Cre–/–); liver-specific Raptor–
KO (Raptorfl/fl|Albumin-Cre+/–) and littermate control (Raptorfl/fl|Albumin-Cre–/–); and GCN2 WT and 
-KO littermates (all on a C57BL/6J background) were bred in our facility as described previously (23). 
Male mice were used in all experiments, except those involving LiTSC1-KO and CREBH-KO mice, in 
which both male and female mice were used.
1 5insight.jci.org   https://doi.org/10.1172/jci.insight.99470
R E S E A R C H  A R T I C L E
Diets
Semipurified diets were purchased from Research Diets. The complete diet was based on D12450BS 
consisting of  20% calories from proteins derived from enzyme-hydrolyzed casein with additional cystine 
supplementation, 70% from carbohydrates, and 10% from fats (Supplemental Table 1). In the PF diet, the 
protein content was replaced with an isocaloric amount of  sucrose (MilliporeSigma). For protein titration 
experiments, a casein-based amino acid formulation made from crystalline amino acids (Ajinomoto) was 
added at 18, 10, 6, 4, 2, or 0 g per 82 g of  PF D12450BS base with sucrose added to 100 g (Supplemental 
Table 2). HFD (D12492) consisted of  20% calories from protein, 20% from carbohydrates, and 60% calo-
ries from fat. PF-HFD was formulated with 40% carbohydrate and 60% fat calories (Supplemental Table 
1). All diets were prepared in a final 1% agar (MilliporeSigma, catalog A1296) formulation. Mice were 
acclimated on an agar-based complete diet for 2 days, followed by AL or restricted (percentage calculated 
based on intake of  complete diet) access to complete or experimental diets for 7 days. For endpoints in 
the fed state, samples were taken at approximately 9 a.m. For endpoints in the fasted state, food was with-
drawn at 9 a.m., and samples were taken approximately 4 hours later.
Body mass and composition analyses
Body mass was determined by measuring body weight on a daily basis at the time of  feeding at approximately 
5 p.m. Body composition was determined in awake animals using an EchoMRI analyzer system (EchoMRI).
TG measurements
Plasma and serum TG in humans and mice, respectively, were determined using a TG determination kit 
from MilliporeSigma (catalog TRO100-1KT). Liver TG levels were determined from the mice injected 
with tyloxapol to estimate hepatic VLDL-TG secretion. For this, approximately 100 mg of  frozen liver was 
homogenized in 600 μl of  PBS. TG levels were determined as above, directly from the liver homogenate. 
TG concentration values were then normalized per mg of  tissue.
Recombinant lipoprotein particle labeling and clearance
For lipoprotein clearance experiments, recombinant lipoproteins containing [3H]-triolein (~0.13 μCi/g 
body weight) were prepared as previously reported (44) and injected via the tail vein into 4-hour–fasted 
mice, and blood was sampled for radioactivity at the indicated time points.
In vivo labeling, isolation, and clearance of VLDL-TG
Albumin conjugation. Albumin was conjugated to [3H]-palmitate as follows: Delipidated endotoxin-free 
BSA (5 g, Thermo Fisher Scientific) was added to 25 ml of  0.9% NaCl solution, prewarmed at 37°C, 
and adjusted to pH 7.4. Separately, a 50-mM cold palmitate solution was prepared by adding 51.2 mg of  
palmitate to 4 ml of  ethanol. The palmitate was suspended by stirring and heating the solution at 60°C, 
while adjusting the pH to 8.5 with NaOH. Then, 250 μl of  this solution was mixed in a 50 ml conical tube 
with 1 mCi of  tritiated palmitate (Perkin Elmer, catalog NET043001MC) and evaporated under nitrogen. 
When dried, the BSA solution (20 ml) was added to the hot-cold palmitate mixture, vortexed vigorously, 
and incubated overnight at 37°C. After filtration through a 0.22-μm filter, the resulting BSA-palmitate 
complex was analyzed for radioactivity in a Tri-Carb 4910TR liquid scintillation counter (PerkinElmer).
In vivo labeling. For in vivo labeling, mice on control or PF diet for 1 week were fasted for 4 hours 
and then injected with tyloxapol at a dose of  500 mg/kg i.v. via the retro-orbital plexus. After 15 min-
utes, 100 μCi of  the [3H]-palmitate-BSA conjugate in 200 μl was injected i.v. via the retro-orbital plexus. 
Forty-five minutes later, mice were terminally exsanguinated for VLDL particle isolation from serum.
Isolation. VLDL particles were isolated from serum by density ultracentrifugation. Serum (50 μl mini-
mum, 1 ml maximum) was adjusted to 1 ml final volume with PBS and a density of  1.006 gr/ml with KBr 
and centrifuged in 1.0 ml clear polycarbonate thick-wall tubes (Beckman Coulter, catalog 355657) using 
an Optima-XE ultra-centrifuge (Beckman Coulter) with a fixed angle aluminum Type 25 rotor (Beckman 
Coulter, catalog 347261) at 80,000 g at 14°C for 22 hours. The top 200 μl containing VLDL particles was 
collected after centrifugation.
In vivo clearance. VLDL-TG hydrolysis and removal from circulation was determined by i.v. injection 
of  100,000 decays per minute (dpm) of  purified VLDL-TG particles in a volume of  200 μl via the retro-
orbital plexus. Blood was drawn at 0.5 minutes to obtain the maximum concentration of  administered 
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counts in circulation and, subsequently, at different time points for calculation of  VLDL-TG removal 
from circulation in a T4910TR β scintillation counter (PerkinElmer).
Estimation of hepatic VLDL secretion rate
VLDL secretion rate was estimated by blocking peripheral LPL with tyloxapol (MilliporeSigma; 500 mg/kg 
in Dulbecco’s PBS (DPBS) i.v. via the retro-orbital plexus) in 4-hour–fasted mice and by subsequently assess-
ing the rate of  TG accumulation in serum over time.
Liver uptake of [3H]-palmitate in vivo
After 4 hours of  fasting, mice were injected i.v. via the retro-orbital plexus with 200 μl of  a 1:1 solution of  
PBS and [3H]-palmitate-BSA conjugate prepared as described above. After 15 minutes, mice were eutha-
nized, and 120 mg of  liver tissue was incubated in 1 ml of  Solvable (Perkin-Elmer, catalog 6NE9100) at 65°C 
until fully dissolved. The digestion (400 μl) was added to 4 ml of  radiation scintillation cocktail (EcoLume, 
MP Biomedicals) and measured in a Tri-Carb 4910TR liquid scintillation counter (PerkinElmer).
Hepatic VLDL lipidation capacity in vivo
After 4 hours of  fasting, mice were injected with tyloxapol i.v. via the retroorbital plexus at a final con-
centration of  500 mg/kg. After 45 minutes, anesthetized mice were injected through the portal vein with 
50,000 dpm of  [3H]-palmitate-BSA conjugate prepared as described above, and serum samples were col-
lected 10 and 15 minutes later. VLDL particles were isolated by ultracentrifugation as above. The VLDL 
particle fraction (50 μl) was added to 4 ml of  scintillation fluid cocktail (EcoLume, MP Biomedicals) and 
read in a Tri-Carb 4910TR liquid scintillation counter (PerkinElmer). VLDL-TGs were then determined 
from the particles, and normalized VLDL incorporation index was obtained by dividing the cpm over the 
concentration of  TGs in 50 μl of  VLDL particles.
Lipidomic analysis
Serum lipidomic profiling was conducted using liquid chromatography separations coupled with 
positive ion mode mass spectrometry–based analysis on a Thermo Exactive Mass Spectrometer as 
described previously (62, 63).
FPLC analysis
Lipoprotein studies were performed as described previously (44). Briefly, pooled plasma was separated by 
FPLC (GE Healthcare) and the lipid concentration was determined in each fraction with Cobas Integra 
Reagent for triglyceride detection adapted to microtiter plates (Roche Diagnostics).
Determination of APOA5 and APOB
APOA5 and APOB-100 were measured by ELISA from mouse serum diluted in PBS (1:10 for APOA5, 
LS-F9345; 1:2,000 for APOB-100, LS-F5909) and human plasma diluted 1:50 for APOA5 (LS-F5818) 
and 1:200 for APOB-100 (LS-F22515, Lifespan Biosciences) according to the manufacturer’s instructions. 
Relative APOA5 amount per VLDL particle was obtained by dividing serum APOA5 by serum APOB 
concentration and was expressed in arbitrary units.
VLDL particle lipidation measurement
VLDL fractions were isolated as above. VLDL-TG concentration was determined and normalized to an equal 
concentration across samples (nTG expressed in mg/ml), by taking a given volume (v, expressed in µl), and dilut-
ing it with PBS. This solution was further diluted 1:4 (dil) with the diluent buffer provided by the APOB ELISA 
kit (LifeSpan Biosceince, catalog LS-F5909). That dilution (100 μl) was then used to determine the total APOB 
protein concentration by adding it undiluted to the ELISA kit and then measuring it following the manufacturer’s 
instructions. TG lipidation state of APOB-100–containing particles was determined using the following formula: 
,
where nTG refers to the normalized TG concentration (in mg/ml), APOB refers to the purified VLDL 
APOB concentration (expressed in μg/ml), and dil is the dilution factor (dil = 4).
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Rapamycin treatment
Mice were injected with vehicle (0.25% PEG 400 in PBS) or rapamycin (1 mg/kg i.p.) daily for up to 4 days.
Immunoblotting
Snap-frozen tissues were homogenized in 1 ml of  lysis buffer (10% glycerol, 1% NP-40, 1 mM MgCl2, 150 
mM NaCl, 50 mM β-glycerophosphate, 20 mM Tris-HCl, pH 7.4) supplemented with a protease inhibitor 
and phosphatase inhibitor cocktails (Thermo Fisher Scientific) with an IKA T10 Ultra-Turrax tissue dis-
penser. Protein content was determined using the Pierce BCA protein assay kit (Thermo Fisher Scientific), 
and 40 μg of  protein extract was resolved by SDS-PAGE and transferred to Immobilon-P polyvinylidene 
difluoride (PDVF) membranes (MilliporeSigma) for immunoblotting. Membranes were incubated over-
night at 4°C with primary antibody diluted in antibody buffer (5% BSA, 0.1% sodium azide in TBST). 
After washing in TBST, membranes were incubated 90 minutes at room temperature with goat anti–mouse 
(catalog P0447) or goat anti–rabbit (catalog P0449) IgG conjugated with horseradish peroxidase (Dako) 
diluted 1:5,000 in 5% skim milk. After extensive washing with TBST, blots were developed using the Super 
Signal West Femto chemiluminescent substrate kit (Pierce, Thermo Fisher Scientific).
Antibodies
For a list of  all primary antibodies, please refer to Supplemental Table 3.
Gene expression analysis
Frozen tissue samples were first homogenized in Qiazol (Qiagen) using a tissue grinder and then RNA was 
isolated using the chloroform:isopropanol precipitation method. cDNA was synthesized from 1 μg of  total 
RNA by random hexamer priming using the Verso cDNA synthesis kit (Thermo Fisher Scientific). qPCR 
reactions were performed with 20 ng of  cDNA as a template using Taq-Pro DNA polymerase (Danville 
Scientific) and SYBR green (Lonza) in a CFX384 touch Real-Time PCR detection system (Bio-Rad). The 
primers used in this study are provided in Supplemental Table 4. Gene expression was determined using 
the equation 2ΔΔCT, with Hprt for normalization. Data are expressed as fold change relative to the control 
group, which is typically WT mice fed a complete diet on an AL basis.
Cell transfection studies
Human HepG-2 hepatoma cells (ATCC HB-8065) cultured in optimized minimal essential media (Opti-
MEM) supplemented with 10% FBS and 1× penicillin-streptomycin, were trypsinized and cultured at a 
density of  5 × 105 cells in 10-cm cell culture dishes for 2 days until they reached 90% confluence. For 
transfection, 25 μg of  plasmid DNA containing an expression cassette coding for an hemagglutinin epitope 
linked to the amino-terminus active fragment of  CREBH (amino acids 1-332, provided by Ann-Hwee Lee, 
from Cornell University, New York, New York, USA) vs. empty vector (46) was transfected in triplicate 
using lipofectamine (Thermo Fisher Scientific) according to the manufacturer’s instructions.
ChIP
ChIP analysis was performed using the ChIP-IT ChIP-Seq kit (Active Motif), following the manufacturer’s 
instructions, with the following specifications: a total of  300 mg of  frozen liver tissues were homogenized 
in the kit’s buffer and sonicated in a 240 V, 50 Hz Misonix ultrasonic homogenizer at 25% of  amplitude 
— pulsed 30 seconds on, 30 seconds off  — for 10 minutes per tissue, using a 3.2 mm microtip probe. A 
total of  4 μg of  Rb anti-CREBH antibody were used. After reversal of  cross-linking and DNA purification, 
qPCR of  the region flanking the TCCACGTGGT-CREBH binding site in the ApoA5 mouse promoter 
was performed using the following primers: forward: 5′-TTTACAGCAGTCATACATAGG-3′; reverse: 
5′-ACCCTCCTTTCCTATATCC-3′.
Confocal microscopy
Frozen liver samples embedded in OCT and sectioned using a cryostat were fixed in 4% (v/v) paraformalde-
hyde (PFH) for 10 minutes, washed in DPBS, and permeabilized in 0.25% Triton X-100 in TBS. After washing 
in TBS, sections were blocked for 30 minutes with blocking buffer (10% [v/v] normal goat serum, 1% [w/v] 
BSA, glycine 0.3 M) and incubated overnight with primary antibody. After washing, sections were incubated 
with a secondary goat anti–rabbit Alexa 568 conjugated (also diluted in blocking buffer) for 2 hours at room 
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temperature. After incubation, tissue sections were washed and mounted in Vectashield mounting medium 
containing DAPI (Vector Laboratories). Cells and tissues were visualized using a Zeiss LSM 880 laser scanning 
confocal microscope and analyzed using ImageJ (NIH) and Adobe Photoshop 11.0.2 (Adobe Systems).
Statistics
Statistical analyses were performed in GraphPad Prism 6.0 or Microsoft Excel using the indicated tests with P 
< 0.05 considered significant. Two-way ANOVA main effect statistics are contained in Supplemental Table 5.
Study approval
Studies involving human subjects were approved by the IRB of  the Washington University in St. Louis (no. 
201011804). All experiments involving mice were conducted with the approval of  the Harvard Medical 
Area IACUC.
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